Back HCV Treatment

HCV Treatment

AASLD 2016: 8-Week Triple Combo Cures Most Patients with Genotype 1-6 Hepatitis C

A 3-drug regimen of sofosbuvir, velpatasvir, and voxilaprevir taken for 8 weeks demonstrated an overall sustained virological response rate of 95% for previously untreated patients with all hepatitis C virus (HCV) genotypes, while a 12-week regimen cured 96%-97% of people who experienced prior treatment failure on direct-acting antivirals (DAAs), according to a set of Phase 3 studies presented last week at the AASLD Liver Meeting in Boston.

alt

Read more:

AASLD 2016: AbbVie Pangenotypic Combination Cures 98% or More Across HCV Genotypes

AbbVie’s combination of glecaprevir and pibrentasvir cured at least 98% of people with hepatitis C in 3 large clinical trials covering 5 out of 6 genotypes of the virus, and it is likely to receive marketing approval in the United States and European Union as the first ribavirin-free pangenotypic direct-acting antiviral combination next year, according to a report at the AASLD Liver Meeting last week in Boston.

alt

Read more:

AASLD 2016: Grazoprevir/ Elbasvir + Sofosbuvir Highly Effective for Hard-to-Treat Genotype 3 HCV Patients

A triple regimen of grazoprevir/elbasvir (Zepatier) plus sofosbuvir (Sovaldi) without ribavirin cured 96% of previously untreated and 97% of treatment-experienced people with hepatitis C virus (HCV) genotype 3 and liver cirrhosis, matching rates seen in easier-to-treat patient groups, according to results from the C-ISLE study presented this week at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston.

alt

Read more:

AASLD 2016: AbbVie Pangenotypic Combination Cures Hard-to-Treat People with HCV Genotype 3

AbbVie’s pangenotypic combination of glecaprevir and pibrentasvir cured almost all of the hardest-to-treat genotype 3 hepatitis C patients -- those with cirrhosis or previous treatment experience -- in a Phase 2 trial, and looks suitable for use as an 8-week regimen for HCV genotypes 2, 4,5 and 6, according to results of studies presented at the AASLD Liver Meeting last week in Boston.

alt

Read more:

AASLD 2016: Real-World Responses to HCV Treatment Among U.S. Veterans Match Best Clinical Trial Results

Direct-acting antiviral treatment is curing people of hepatitis C in real-world clinical practice at similar rates to those seen in clinical trials, and there do not seem to be major differences between drug regimens, according to results of a large population study presented this weekend at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston.

alt

Read more: